Clinical Policy: Fertility Preservation
Reference Number: CP.MP.130
Last Review Date: 09/20

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Male and female fertility may be transiently or permanently affected by medical treatments such as gonadotoxic therapy, cytotoxic chemotherapy, or radiation therapy, as well as by other iatrogenic causes. Rates of permanent infertility and compromised fertility after medical treatment vary and depend on many factors, including the drug, size and location of the radiation field if applicable, dose, dose-intensity, method of administration (oral versus intravenous), disease, age, treatment type and dosages, and pretreatment fertility.

Policy/Criteria
I. It is the policy of health plans affiliated with Centene Corporation® that, when a covered benefit under the member’s/enrollee’s benefit plan contract, any of the following procedures are medically necessary for women and adolescent girls prior to commencing treatment that is likely to cause infertility (excluding voluntary sterilization):
   A. Embryo cryopreservation;
   B. Cryopreservation of mature oocytes;
   C. Ovarian transposition (oophoropexy);
   D. Radiation (gonadal) shielding;
   E. Conservative gynecologic surgery including but not limited to the following:
      1. Radical trachelectomy in early stage cervical cancer (i.e., stage IA2 to IB cervical cancer with diameter <2 cm and invasion <10 mm);
      2. Ovarian cystectomy for early-stage ovarian cancer.

II. It is the policy of health plans affiliated with Centene Corporation that, when a covered benefit under the member’s/enrollee’s benefit plan contract, the following procedures are medically necessary for men and adolescent boys prior to commencing treatment that is likely to cause infertility (excluding voluntary sterilization):
    A. Cryopreservation of sperm;
    B. Radiation (gonadal) shielding.

III. It is the policy of health plans affiliated with Centene Corporation that there is insufficient evidence in the published peer-reviewed literature to support the use of the following procedures for women and adolescent girls prior to commencing treatment that is likely to affect fertility:
    A. Cryopreservation of immature oocytes;
    B. Ovarian tissue cryopreservation and transplantation procedures;
    C. Ovarian suppression with gonadotropin releasing hormone (GnRHa) or antagonists.

IV. It is the policy of health plans affiliated with Centene Corporation that there is insufficient evidence in the published peer-reviewed literature to support the use of the following
procedures for men and adolescent boys prior to commencing treatment that is likely to affect fertility:
A. Testicular suppression with GnRHa or antagonists;
B. Testicular tissue or spermatogonial cryopreservation;
C. Reimplantation or grafting of human testicular tissue.

Background
The most frequent cause of impaired fertility in male cancer survivors is chemotherapy or radiation-induced damage to sperm. The fertility of female survivors may be impaired by any treatment that damages immature eggs, affects the body’s hormonal balance, or injures the reproductive organs. Fertility preservation is an essential part of the management of adolescents and young adults who are at risk for infertility due to cancer treatments, or bilateral ovary or testicular removal for treatment of disease.

Embryo cryopreservation is an established fertility preservation method, and it has routinely been used for storing surplus embryos after in vitro fertilization. Cryopreservation of unfertilized oocytes is an option, particularly for patients who do not have a male partner, do not wish to use donor sperm, or have religious or ethical objections to embryo freezing. Success rates for this procedure have improved significantly, with some reproductive specialty centers reporting success rates comparable to those obtained using unfrozen eggs, especially in younger women. Like embryo cryopreservation, this technique also requires ovarian stimulation and ultrasound-guided oocyte retrieval.

The effectiveness of ovarian suppression with GnRHa or antagonists is inconclusive. There is conflicting evidence to recommend GnRHa as a method of fertility preservation. Studies to date have not provided definitive data demonstrating that GnRHa preserves fertility, and it remains the subject of ongoing research.

American Society of Clinical Oncology (ASCO)
ASCO’s recommends discussing fertility preservation with all patients of reproductive age (and with parents or guardians of children and adolescents) if infertility is a potential risk of therapy, as early as possible, before treatment starts.

For males who express an interest in fertility preservation, sperm cryopreservation is the only established fertility preservation method. ASCO notes that hormonal therapy in men has not shown to be successful in preserving fertility. Per ASCO, other methods, including testicular tissue cryopreservation for the purpose of future reimplantation or grafting of human testicular tissue are experimental.

For females who express an interest in fertility preservation, both embryo and oocyte cryopreservation are established fertility preservation methods. Other options for women include ovarian transposition (oophoroexy) when pelvic radiation therapy for cancer treatment is performed or conservative gynecological surgery and radiation options. ASCO notes that ovarian tissue cryopreservation for the purpose of future transplantation is experimental. They note also, there is insufficient evidence regarding the effectiveness of ovarian suppression (gonadotropin-releasing hormone analogs) to preserve fertility.
The ASCO guidelines continue to note that there is conflicting evidence to recommend GnRHa and other means of ovarian suppression for fertility preservation. However, the Panel recognizes that, when proven fertility preservation methods are not feasible, and in the setting of young women with breast cancer, GnRHa may be offered to patients in the hope of reducing the likelihood of chemotherapy-induced ovarian insufficiency. GnRHa should not be used in place of proven fertility preservation methods. The panel notes that the field of ovarian tissue cryopreservation is advancing quickly and may evolve to become standard therapy in the future, although at the time of publication, it remains experimental.10

For children, ASCO recommends using established methods of fertility preservation (sperm cryopreservation and oocyte cryopreservation) for postpubertal minor children, with patient assent, if appropriate, and parent or guardian consent.1 For prepubertal children, the only fertility preservation options are ovarian and testicular cryopreservation, which are investigational.10

**National Comprehensive Cancer Network (NCCN)**

NCCN guidelines on Adolescent and Young Adult Oncology note that mature oocyte cryopreservation is no longer considered investigational, however, embryo cryopreservation is preferred if there is an identified sperm donor.2

Ovarian tissue cryopreservation is a promising, but less well-studied strategy for female fertility preservation when there is insufficient time for oocyte or embryo cryopreservation and/or the patient is prepubertal. While tissue cryopreservation is still considered investigational at some institutions, it may be discussed as an option for fertility preservation.2

Some data suggest that menstrual suppression with GnRHa may protect ovarian function. However, evidence that menstrual suppression with GnRHa protect ovarian function is insufficient, so this procedure is not currently recommended as an option for fertility preservation.2

**American College of Obstetricians and Gynecologists (ACOG)**

For young women who have completed sexual development, GnRHa, such as leuprolide acetate, have been used to induce ovarian quiescence to preserve ovarian function and fertility after cytotoxic treatment. Leuprolide acetate is not recommended for prepubertal girls. There still is no conclusive evidence that demonstrates efficacy of GnRHa, and studies are primarily observational regarding their effectiveness in fertility preservation. The use of GnRHa should be considered and discussed with premenopausal patients who will be treated with chemotherapeutic agents. Because GnRHa have mixed results in fertility preservation with trends toward more favorable outcomes, GnRHa therapy may be recommended as an adjuvant to chemotherapy. A meta-analysis of females 14–45 years of age demonstrated that co-treatment with GnRH agonists during chemotherapy was associated with increased odds of maintaining ovarian function and achieving pregnancy after treatment.11

**Coding Implications**
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00840</td>
<td>Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified</td>
</tr>
<tr>
<td>57531</td>
<td>Radical trachelectomy, with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling biopsy, with or without removal of tube(s), with or without removal of ovary(s)</td>
</tr>
<tr>
<td>58825</td>
<td>Transposition, ovary(s)</td>
</tr>
<tr>
<td>58970</td>
<td>Follicle Puncture for oocyte retrieval, any method</td>
</tr>
<tr>
<td>76856</td>
<td>Ultrasound, pelvic (nonobstetric), real time with image documentation; complete</td>
</tr>
<tr>
<td>76948</td>
<td>Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation</td>
</tr>
<tr>
<td>77334</td>
<td>Treatment devices, design and construction, complex (irregular blocks, special shields, compensators, wedges, molds or casts)</td>
</tr>
<tr>
<td>82670</td>
<td>Estradiol; total</td>
</tr>
<tr>
<td>83001</td>
<td>Gonadotropin; follicle stimulating hormone (FSH)</td>
</tr>
<tr>
<td>83002</td>
<td>Gonadotropin; luteinizing hormone (LH)</td>
</tr>
<tr>
<td>84144</td>
<td>Progesterone</td>
</tr>
<tr>
<td>84702</td>
<td>Gonadotropin; chorionic (hCG); quantitative</td>
</tr>
<tr>
<td>89250</td>
<td>Culture of oocyte(s)/embryo(s), less than 4 days</td>
</tr>
<tr>
<td>89251</td>
<td>Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos</td>
</tr>
<tr>
<td>89254</td>
<td>Oocyte identification from follicular fluid</td>
</tr>
<tr>
<td>89258</td>
<td>Cryopreservation, embryo(s) (freezing services, not storage)</td>
</tr>
<tr>
<td>89259</td>
<td>Cryopreservation; sperm</td>
</tr>
<tr>
<td>89268</td>
<td>Insemination of oocytes</td>
</tr>
<tr>
<td>89272</td>
<td>Extended culture of oocytes/embryo(s), 4-7 days</td>
</tr>
<tr>
<td>89280</td>
<td>Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes</td>
</tr>
<tr>
<td>89281</td>
<td>Assisted oocyte fertilization, microtechnique; greater than 10 oocytes</td>
</tr>
<tr>
<td>89320</td>
<td>Semen analysis; volume, count motility and differential</td>
</tr>
<tr>
<td>89337</td>
<td>Cryopreservation, mature oocyte(s)</td>
</tr>
<tr>
<td>89352</td>
<td>Thawing of cryopreserved; embryo(s)</td>
</tr>
<tr>
<td>89353</td>
<td>Thawing of cryopreserved; sperm/semen, each aliquot</td>
</tr>
<tr>
<td>99000</td>
<td>Handling and/or conveyance of specimen for transfer from office to a laboratory</td>
</tr>
<tr>
<td>99001</td>
<td>Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)</td>
</tr>
<tr>
<td>99070</td>
<td>Supplies and materials (except spectacles), provided by the physician or other qualified health care professional over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies, or materials provided)</td>
</tr>
</tbody>
</table>
**CPT® Codes** | **Description**
---|---
99078 | Physician or other qualified health care professional qualified by education, training, licensure/regulation (when applicable) educational services in a group setting (eg, prenatal, obesity, or diabetic instructions)
99199 | Unlisted special service, procedure or report

**HCPCS Codes** | **Description**
---|---
S4030 | Sperm procurement and cryopreservation services; initial visit
S4031 | Sperm procurement and cryopreservation services; subsequent visit

**CPT Codes Considered Investigational**

| **CPT® Codes** | **Description** |
---|---|
89335 | Cryopreservation, reproductive tissue, testicular

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

| **ICD-10-CM Code** | **Description** |
---|---|
C00.0-D49 | Neoplasms
D27.0 | Benign neoplasm of right ovary
D27.1 | Benign neoplasm of left ovary
D39.10-D39.12 | Neoplasm of uncertain behavior of ovary
D40.10-D40.12 | Neoplasm of uncertain behavior of testis
N70.01-N70.03 | Acute salpingitis and oophoritis
N70.11-N70.13 | Chronic salpingitis and oophoritis
N83.511-N83.519 | Torsion of ovary and ovarian pedicle
Z31.84 | Encounter for fertility preservation procedure

**Reviews, Revisions, and Approvals**

| **Policy/Date/Approval** | **Date** | **Approval Date** |
---|---|---|
Policy adopted from Health Net NMP512, Fertility Preservation in Cancer Patients. Expanded criteria to include iatrogenic causes of infertility. Added the following ICD-10 codes: D27.0, D27.1, N70.03, N70.13, N83.51. | 9/16 | 10/16 |
Added the following to medical necessity statements in I. and II: “when a covered benefit under the member’s benefit plan contract.” References reviewed and updated. Codes updates | 09/17 | 10/17 |
Clarified I.B. that cryopreservation is medically necessary for “mature” oocytes; Under III, added A. Cryopreservation of immature oocytes, as investigational; Updated recommendations from professional societies in the background; references reviewed and updated; codes reviewed. | 09/18 | 09/18 |
Annual review completed. Codes reviewed. References reviewed and updated. Specialty review completed. | 09/19 | 09/19 |
Removed CPT 0375T – code deleted 1/1/20 | 04/20 | |
References reviewed and updated. Replaced “members” with “members/enrollees” in all instances | 09/20 | 09/20 |
Revised description of CPT-82670. CPT-0058T deleted in 2021. “Experimental/investigational” verbiage replaced with descriptive language in policy statement III and IV.

<table>
<thead>
<tr>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/21</td>
<td></td>
</tr>
</tbody>
</table>

- **References**

  
  
  
  
  
  
  
  
  
  
  

**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.
CLINICAL POLICY
Fertility Preservation

**Note: For Medicaid members/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at [http://www.cms.gov](http://www.cms.gov) for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.